Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AKBA
Strong SellSinkerAkebia Therapeutics, Inc. · Healthcare · United States · $243M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company's lead product, Vafseo (vadadustat), is an oral HIF-PH inhibitor designed to treat anemia associated with chronic kidney disease. Akebia's competitive position is anchored by its specialized renal pipeline and established commercial infrastructure in the nephrology market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 292.5M | 194.6M | 160.2M | 236.2M | -6.9% | 219.1M | 196.8M | 140.0M | -23.0% |
| EPS | -0.51 | -0.28 | -0.33 | -0.02 | — | -0.12 | -0.16 | -0.33 | — |
| Shares | 184.1M | 194.6M | 224.8M | 265.4M | +44.1% | 277.1M | — | — | — |
| Debt | 99.8M | 48.1M | 47.6M | 51.8M | -19.6% | 199.2M | — | — | — |
| Equity | 5.2M | -30.6M | -49.2M | 32.6M | 84.1% | — | — | — | — |
| Op CF | -73.2M | -23.4M | -40.7M | 68.0M | — | 41.6M | — | — | — |
| Inv CF | -0.1M | 0 | -33.0K | -7.9M | — | — | — | — | — |
| Fin CF | 14.6M | -25.2M | 49.7M | 72.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKBA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc.(you) | $243M | 17 | Strong Sell |
| LFCR | Lifecore Biomedical, Inc. | $172M | 16 | Strong Sell |
| DERM | Journey Medical Corporation | $211M | 24 | Sell |
| ORGO | Organogenesis Holdings Inc. | $224M | 29 | Sell |
| SIGA | SIGA Technologies, Inc. | $220M | 30 | Sell |
| BIOA | BioAge Labs, Inc. | $443M | 9 | Strong Sell |
| AQST | Aquestive Therapeutics, Inc. | $630M | 14 | Strong Sell |
| CWEB.TO | Charlotte's Web Holdings, Inc. | $80M | 15 | Strong Sell |
| GLAS | Glass House Brands Inc. | $931M | 18 | Strong Sell |
| CL.CN | Cresco Labs Inc. | $291M | 43 | Hold |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%